Quantcast

Latest Psoriatic arthritis Stories

2014-05-05 00:21:27

COVA322 is First of Covagen's Bispecific FynomAbs to Enter Clinical Trials ZURICH-SCHLIEREN, Switzerland, May 5, 2014 /PRNewswire/ -- Covagen today announced it has initiated a Phase Ib/IIa study with COVA322, a bispecific TNF/IL-17A inhibitor. COVA322 is Covagen's lead bispecific FynomAb® developed for treatment of patients with rheumatoid arthritis, psoriatic arthritis and other inflammatory diseases. The trial will enroll 39 patients with psoriasis and evaluate safety as well as...

2014-05-01 12:32:22

Patented French maritime pine bark extract shown to significantly reduce the most common signs of psoriasis by reducing inflammation, increasing skin hydration and fighting free radicals HOBOKEN, N.J., May 1, 2014 /PRNewswire/ -- A new peer-reviewed study published in the March issue of the Panminerva Medica found that supplementation with Pycnogenol(®) (pic-noj-en-all), a standardized natural plant extract from French maritime pine tree bark, significantly improves the painful and visible...

2014-04-30 12:30:11

Expert Opinion Indicates That Humira and Cimzia Have the Best Clinical Profiles of Key Marketed Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., April 30, 2014 /PRNewswire/ --Decision Resources Group finds that, when asked to select the top three most persuasive end points when prescribing a new drug for psoriatic arthritis (PsA), the highest percentages of surveyed United States and European rheumatologists selected the American College of Rheumatology (ACR)...

2014-04-28 08:28:32

Celebrate the Spirit of Arthritis Awareness Month by Participating in the Walk to Cure Arthritis in Your Community LOS ANGELES, April 28, 2014 /PRNewswire-USNewswire/ -- Help find a cure by participating in and fundraising for the 2014 Walk to Cure Arthritis. Formerly known as Arthritis Walk, Walk to Cure Arthritis is the Arthritis Foundation's signature, national fundraising event to prevent, control and cure the nation's leading cause of disability. Funds raised through local...

2014-04-24 12:29:49

First U.S. registry to collect both physician and patient data on psoriatic arthritis PORTLAND, Ore., April 24, 2014 /PRNewswire-USNewswire/ -- To improve treatment decisions and patient outcomes for psoriatic arthritis (PsA)--a chronic inflammatory arthritis that affects the joints and tendons--the National Psoriasis Foundation (NPF) and Corrona, LLC (Corrona) are collaborating to give NPF-affiliated researchers access to Corrona's psoriatic arthritis registry, which is the largest...

2014-04-20 23:01:04

ReportsnReports.com offers Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral drugs and Biologics to Change Future Treatment Paradigm market research report in its store. Dallas, TX (PRWEB) April 20, 2014 Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral drugs and Biologics to Change Future Treatment Paradigm market research report says that over the last decades, therapeutic options for Plaque...

2014-04-16 23:14:45

In May, over three dozen nonprofits around the world, along with thousands of patients, supporters, practitioners, and researchers, will unite under one ‘virtual roof’ to participate in the largest educational & awareness event in Autoimmune Arthritis history. Los Angeles, CA (PRWEB) April 16, 2014 At 6am ET/USA on May 19th, 2014, the online Virtual Convention doors to World Autoimmune Arthritis Day (WAAD14) will open and 1,000’s of attendees from dozens of countries around the...

2014-04-14 20:22:24

FORT WORTH, Texas, April 14, 2014 /PRNewswire/ -- ReCept announces that it is among a select group of specialty pharmacies selected by Celgene to distribute Otezla® (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla® is an oral small-molecule which works by blocking the enzyme phosphodiesterase 4 to reduce swelling in joints and improve physical function in a form of arthritis that afflicts psoriasis sufferers. Approved by the FDA on March 21, 2014 and...

2014-04-10 11:29:47

Rheumatoid arthritis patients are likelier than the average person to develop chronic kidney disease, and more severe inflammation in the first year of rheumatoid arthritis, corticosteroid use, high blood pressure and obesity are among the risk factors, new Mayo Clinic research shows.  Physicians should test rheumatoid arthritis patients periodically for signs of kidney problems, and patients should work to keep blood pressure under control, avoid a high-salt diet, and eliminate or scale...

2014-04-04 12:27:14

FLINT, Mich., April 4, 2014 /PRNewswire-iReach/ -- Diplomat has announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla® (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla® is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). Otezla® was approved by the FDA on March 21, 2014, and is available in 10 mg, 20 mg and 30 mg tablets. Diplomat...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related